Rexulti
These highlights do not include all the information needed to use REXULTI safely and effectively. See full prescribing information for REXULTI. REXULTI® (brexpiprazole) tablets, for oral use Initial U.S. Approval: 2015
2d301358-6291-4ec1-bd87-37b4ad9bd850
HUMAN PRESCRIPTION DRUG LABEL
May 15, 2023
Otsuka America Pharmaceutical, Inc.
DUNS: 008314390
Products 8
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
brexpiprazole
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (13)
brexpiprazole
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (12)
brexpiprazole
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (12)
brexpiprazole
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (12)
brexpiprazole
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (11)
BREXPIPRAZOLE
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
BREXPIPRAZOLE
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
brexpiprazole
Product Details
FDA regulatory identification and product classification information